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Abstract
In this study, 19 dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-
dihydropyranoxanthone (DCX) derivatives, previously discovered as novel anti-HIV agents, were
evaluated for their potential to reverse multi-drug resistance (MDR) in a cancer cell line over-
expressing P-glycoprotein (P-gp). Seven compounds fully reversed resistance to vincristine (VCR)
at 4 μM, a 20-fold enhancement compared to the first generation chemosensitizer, verapamil (4
μM). The mechanism of action of DCPs and DCXs was also resolved, since the most active
compounds (3, 4, and 7) significantly increased intracellular drug accumulation due, in part, to
inhibiting the P-gp mediated drug efflux from cells. We conclude that DCPs (3 and 4) and DCXs
(7, 11, and 17) can exhibit polypharmacologic behavior by acting as dual inhibitors of HIV
replication and chemoresistance mediated by P-gp. As such, they may be useful in combination
therapy to overcome P-gp-associated drug resistance for AIDS treatment.
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The first and best characterized mammalian drug-efflux pump, the ATP-binding cassette
(ABC), P-glycoprotein (P-gp), is known to play a significant role in anti-HIV drug
absorption and disposition.1 Even after several years of highly active anti-retrovirus
treatment (HAART), failure to eradicate HIV in P-gp distributed reservoirs, such as the
brain and HIV-infected lymphocytes, as well as multi-drug resistance (MDR),2–4 are both
attributed in part to P-gp expression. Among current anti-HIV drugs, most protease
inhibitors (PIs) and selected non-nucleoside reverse transcriptase inhibitors (NNRTIs) have
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been identified either as P-gp substrates or as inducers of P-gp expression.5 It is the
expression of P-gp that accounts for reductions in both intracellular concentration and
bioavailability of AIDS drugs.6 Therefore, a novel anti-HIV agent having MDR reversal
action should, in principle, have a dual benefit for combination (HAART) therapy since it
would target HIV replication and improve the bioavailability of other anti-HIV agents used
in the combination that are P-gp substrates.
Pyranochromone derivatives, analogs of dicamphanoyl-dihydropyranochromone (DCP) and
dicamphanoyl-dihydropyranoxanthone (DCX) (Figure 1), were previously identified in one
of our laboratories as potent anti-HIV agents against both wild-type and drug-resistant HIV
strains, with unique molecular structures and mechanism of action.7, 8 Since the structural
features, including the conjugated planar system and bulky side chains at the 3′ and 4′
positions, share certain similarities to current pharmacophore model for P-gp inhibitors,9 we
hypothesised that these compounds might serve as P-gp inhibitors to reverse P-gp efflux
potency and function in P-gp over-expressed cancer cells. To evaluate our hypothesis, DCP
and DCX analogs with high anti-HIV selectivity were synthesized 7, 8, 10 and tested by
following a two-step bio-assay to (1) determine their capacity to reverse VCR resistance of
MDR-1 cancer cells and (2) measure P-gp-mediated drug efflux. As reported herein, we
have successfully identified dual-function anti-HIV agents using this approach.
DCP and DCX analogs were synthesized following literature methods reported earlier, as
illustrated in Scheme 1.7, 8, 10 Briefly, reaction of 20 or 23 with ethyl alkanoates or
hydroxybenzoic acids under appropriate conditions gave hydroxylated chromone (21) and
xanthone (24), respectively. Reaction of the resulting compounds with a pyrano moiety
through alkylation and cyclization yielded 22 and 25. After asymmetric dihydroxylation and
esterification, the final products 1–19 were obtained.
Compounds 1–19 are potent anti-HIV agents with activity starting from 0.06 μM and
0.07μM against wild-type and multidrug-resistant HIV strains, respectively, and with low
selective cytotoxicity against the host TZM-bl cell line (IC50 generally over 10 μM).7, 8 In
this study, the ability of these anti-HIV compounds to reverse MDR using a P-gp over-
expressed cancer cell line (KB-vin) was evaluated by measuring the reversal of vincristine
(VCR) resistance in the presence of 4 μM of DCP or DCX analogs. Verapamil, a first
generation chemosensitizer and P-gp competitive inhibitor, was used as the positive control.
The results are shown in Table 1. In general, the DCP and DCX analogs dramatically
reversed the VCR resistance in the KB-vin cells by lowering the GI50 values of VCR under
co-treatment conditions.
DCP analogs 3 and 4, with a methyl group substituted at R2, afforded a ten-fold better
chemosensitization than their counterparts 1 and 2, as shown in Table 1. (The GI50 of VCR
is 2.9 or 3.9 nM in combination with compound 3 or 4, versus 30 or 20 nM in combination
with compound 1 or 2.) This suggests that R2-methyl in DCP is important for optimizing the
activity. The small alkyl group is also tolerated well at R1 in DCP. Both 3 and 4 exerted high
activity significantly better than verapamil. Both compounds also showed potent anti-HIC
activity. Significantly, compound 3 fully reversed the VCR resistance in KB-vin under the
co-treatment condition (with GI50 of 2.0 nM for VCR in the parent drug-sensitive KB cell
line).
Compounds 5–19 are DCX analogs with diverse substitutions on the A and C rings. As
shown in Table 1, most of the analogs exhibited high chemosensitization activity, indicating
that a planar ring extension from chromone to xanthone is not detrimental. Compounds 5–7
bearing different substitutions on R7 afforded the antiviral compounds with a wide spectrum
of chemosensitization activities. Compounds 5 and 7 with non-substitution or R7-methoxy-
Zhou et al. Page 2













substitution exhibited comparable effects to 3 and 4, with co-treatment GI50s as low as 2.1
and 3.4 nM, respectively. In contrast, 6, an R7-hydroxy-DCX, failed to reverse the
cytotoxicity of VCR at 4μM. The SAR could be explained if the oxo group in the B ring
functions as an H-bonding acceptor important for the interaction with the target protein, the
R7-OH group may destroy the interaction by forming the intramolecular H-bonding.
Compounds 8–18 contain diverse substitutions around the A-ring. Generally, an alkyl,
alkoxy, or fluoride substituent at R3 or R6 sustained or enhanced the chemosensitization
activity compared with 5 and 7. Compounds 8, 11, 12, and 16 fully reversed VCR resistance
with co-treatment GI50 values around 2–3 nM. Compounds with R4 or R5 substituents (9,
10, 13, 14, 15 and 18) showed no significant chemosensitizion activity, although some of
them were good HIV inhibitors, suggesting that chemosensitizion activity is sensitive to the
substitutions at R4 or R5. Extension/modification on the ring system horizontally or
increasing the molecular hindrance was unfavorable for the interaction of the drug
molecules with the target protein(s), such as P-gp. Compound 17, with a fluoro moiety at
R5, demonstrated a comparable chemosensitizion activity to the non-F-substituted analog 7
and its positional isomer 16. This result could be attributed to the isosteric relationship of F
vs H. It is interesting that introducing bromide at R8 (compound 19) significantly improved
MDR reversal activity approximately two-fold compared to compound 7, with a co-
treatment GI50 value as low as 1.6 nM, indicating that R8 may be an important position for
optimizing chemosensitization activity. Further investigation is needed to verify and extend
the preliminary SAR considerations noted above.
Data shown in Table 1 demonstrated a lack of concordance between anti-HIV activity and
MDR reversal potency. Some compounds, such as compounds 1, 2, and 9, were potent anti-
HIV inhibitors, but weaker chemosensitizers. In contrast, compounds 5, 8, and 12
significantly reversed VCR resistance, but only weakly inhibited anti-HIV replication. This
finding is not too surprising, since different targets are presumably involved. Nevertheless,
compounds 3, 4, 7, 11, and 17 exhibited significant polypharmacology and, as such, are
interesting dual function anti-HIV and chemosensitization leads.
It is known that the acquired VCR resistance in KB-Vin is due to the enhanced drug efflux
via P-gp over-expression.12, 13 Since the addition of DCP and DCX reversed VCR’s
cytotoxicity as determined by phenotypic assay, we next investigated whether select
compounds were active using a P-gp functional assay. The effect of DCP or DCX analogs
on efflux of the P-gp substrate Doxorubicin (Dox) was determined using an established
fluorometric cell-based assay. In this assay, inhibition of P-gp leads to the intracellular
accumulation of Dox, a fluorescent anthracycline cancer drug, which serves as a quantitative
measurement of P-gp inhibition.14–16 Three compounds with the most active
chemosensitization action (3, 4, and 7 in Table 1) were tested for their ability to facilitate
Dox influx in comparison to the positive control inhibitor, verapamil. The results are shown
in Figure 2. All three compounds induced significant intracellular accumulation of Dox
under co-treatment conditions, and all were more active than the positive control compound,
verapamil. The results suggest that chemosensitization by DCP and DCX analogs can be
attributed in part to the inhibition of P-gp efflux activity in the KB-MDR-1 cell system.
Further work is needed to determine whether P-gp inhibition is the sole mechanism of
chemosensitization by these novel anti-HIV compounds.
In summary, nineteen pyranochromone derivatives (DCPs and DCXs) with selective anti-
HIV activity were tested using a phenotypic assay for chemosensitization activity. Most
derivatives evaluated were better chemosensitizers than the control agent verapamil. Seven
of them (3, 5, 8, 11, 12, 17 and 19) fully reversed VCR resistance under the co-treatment
condition used. In general, the SAR profiles of chemosensitization and anti-HIV activities
were not concordant but five compounds, 3, 4, 7, 11 and 17, showed significant dual
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pharmacologic actions. Using a P-gp functional assay, the inhibition of cancer drug efflux
was demonstrated in co-treated cells, suggesting a likely mechanism for the
chemosensitization action involves P-gp inhibition. Taken together, our results show that
several pyranochromone derivatives possessing potent anti-HIV activity also exert
substantial chemosensitization activity via P-gp inhibition. In principle, this unique, dual-
function behavior would make these ideal candidates for exploring new combination
(HAART) therapies since they are a novel mechanistic class of reverse transcriptase
inhibitor (RTI) that could sensitize and increase efficacy of other anti-HIV drugs that are P-
gp substrates. Work is ongoing to better define the mechanism of action of these
pyranochromone derivatives and to establish pre-clinical anti-HIV activity in combination
regimens.
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dodecyl sulfate (SDS) in PBS. Dox-associated mean fluorescence intensity was measured at Ex =
488 nm and Em = 580 nm with a fluorescence microplate reader (Plate Chameleon Multilabel
Detection Platform, Hidex Oy, Turku, Finland) with MikroWin software. Verapamil, as a known
P-gp inhibitor/modulator, was used as the positive control. All the data were calculated as the ratio
of dox fluorescence with test compound divided by dox fluorescence without test compound after
subtraction of the fluorescence of the control.
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Structures of DCP and DCX.
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Reactions and Conditions: (i)ethyl alkanoates, NaH, THF, reflux, amberlyst 15 resin,
isopropanol reflux; (ii) 4,4-dimethoxy-2-methyl-2-butanol, pyridine, microwave; (iii)
K3Fe(CN)6, (DHQ)2PYR, K2OsO2(OH)4, K2CO3, methanesulfonamide, t-butanol/H2O,
0°C; (iv) (S)-camphanoyl chloride, DMAP, CH2Cl2, (v) 2-hydroxybenzoic acids, Eaton’s
reagent, reflux; (vi) NBS, CH2Cl2.
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